Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Hyperkeratosis Palmaris et Plantaris

erlotinib hydrochloride has been researched along with Hyperkeratosis Palmaris et Plantaris in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (14.29)24.3611
2020's6 (85.71)2.80

Authors

AuthorsStudies
Lee, G; Lowe, PM1
Basset, J; Hovnanian, A; Marchal, L1
Assaf, S; Bergson, S; Feller, Y; Giladi, M; Malovitski, K; Mohamad, J; Pavlovsky, M; Sarig, O; Sprecher, E1
Diab, Y; Diamond, C; Duchatelet, S; Hill, I; Hovnanian, A; Kirkorian, AY; Lakdawala, N; Marathe, K; Richard, G; Siegel, DH; Tower, RL; Watanabe, F; Zhang, A1
Bodemer, C; Boucheix, C; Chaumon, S; Doz, F; Greco, C; Hadj-Rabia, S; Leclerc-Mercier, S; Molina, T1
Noakes, R1
Kenner-Bell, BM; Lacouture, ME; Paller, AS1

Other Studies

7 other study(ies) available for erlotinib hydrochloride and Hyperkeratosis Palmaris et Plantaris

ArticleYear
Treatment of Keratin 16 Palmoplantar Keratoderma With Topical Erlotinib.
    JAMA dermatology, 2022, 02-01, Volume: 158, Issue:2

    Topics: Erlotinib Hydrochloride; Humans; Keratin-16; Keratins; Keratoderma, Palmoplantar; Mutation; Pedigree

2022
EGFR Signaling Is Overactive in Pachyonychia Congenita: Effective Treatment with Oral Erlotinib.
    The Journal of investigative dermatology, 2023, Volume: 143, Issue:2

    Topics: ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratoderma, Palmoplantar; Mutation; Pachyonychia Congenita; Pain; Quality of Life

2023
Defective cathepsin Z affects EGFR expression and causes autosomal dominant palmoplantar keratoderma.
    The British journal of dermatology, 2023, 08-24, Volume: 189, Issue:3

    Topics: Cathepsin Z; ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratoderma, Palmoplantar; Skin

2023
Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome.
    JAMA dermatology, 2020, 02-01, Volume: 156, Issue:2

    Topics: Adolescent; Brazil; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunosuppressive Agents; Infant; Keratoderma, Palmoplantar; Male; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; Syndrome; TOR Serine-Threonine Kinases; Treatment Outcome

2020
Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations.
    JAMA dermatology, 2020, 02-01, Volume: 156, Issue:2

    Topics: Adolescent; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Keratoderma, Palmoplantar; Male; Mutation; Protein Kinase Inhibitors; Syndrome; TRPV Cation Channels

2020
Olmsted Syndrome: Response to erlotinib therapy and genotype/phenotype correlation.
    The Australasian journal of dermatology, 2021, Volume: 62, Issue:3

    Topics: Adult; Erlotinib Hydrochloride; Female; Genetic Profile; Humans; Keratoderma, Palmoplantar; Treatment Outcome

2021
Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma.
    Journal of the American Academy of Dermatology, 2010, Volume: 63, Issue:2

    Topics: Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Protein Kinase Inhibitors; Quinazolines

2010